



The Cochrane review of electronic cigarettes for smoking cessation: remaining focused on the evidence

Caitlin Notley¹, Ailsa R. Butler², Nicola Lindson³, Chris Bullen⁴, Annika Theodoulou², Rachna Begh², Hayden McRobbie^{5,6}, Peter Hajek⁷, Nancy Rigotti⁸ and Jamie Hartman-Boyce³

¹University of East Anglia, Medical School, Norwich, UK. ²University of Oxford, Oxford, UK. ³University of Oxford, Medical Sciences Division, Nuffield Dept of Primary Care Health Sciences, Oxford, UK. ⁴University of Auckland, Auckland, New Zealand. ⁵University of New South Wales, National Drug and Alcohol Research Centre, Sydney, Australia. ⁶Lakes District Health Board, Rotorua, New Zealand. ⁷Wolfson Institute of Preventive Medicine, London, UK. ⁸Harvard Medical School, MGH Tobacco Research and Treatment Center, Boston, MA, USA.

Caitlin Notley (C.Notley@uea.ac.uk)



Shareable abstract (@ERSpublications)

Evaluating new and emerging technologies for helping more people who smoke to quit is vital. The authors respond to a previous commentary on the Cochrane review, presenting the evidence using gold standard Cochrane methods. <https://bit.ly/3xDcv8B>

Cite this article as: Notley C, Butler AR, Lindson N, *et al.* The Cochrane review of electronic cigarettes for smoking cessation: remaining focused on the evidence. *Eur Respir J* 2021; 58: 2102117 [DOI: 10.1183/13993003.02117-2021].

This single-page version can be shared freely online.

Copyright ©The authors 2021. For reproduction rights and permissions contact permissions@ersnet.org

Received: 29 July 2021
Accepted: 05 Aug 2021

Reply to C. Pisinger and J. Vestbo:

We are grateful for the opportunity to reply to the commentary on our Cochrane review of electronic cigarettes (EC) for smoking cessation [1] posed by PISINGER and VESTBO [2] with subsequent commentary by McALINDEN *et al.* [3].